ACCOUNTS - Final Accounts preparation


Caseware UK (AP4) 2022.0.179 2022.0.179 2022-09-302022-09-302023-05-1712021-10-01falseResearch and experimental development on biotechnology1falseThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 12189862 2021-10-01 2022-09-30 12189862 2020-10-01 2021-09-30 12189862 2022-09-30 12189862 2021-09-30 12189862 c:Director1 2021-10-01 2022-09-30 12189862 d:CurrentFinancialInstruments 2022-09-30 12189862 d:CurrentFinancialInstruments 2021-09-30 12189862 c:AuditExempt-NoAccountantsReport 2021-10-01 2022-09-30 12189862 c:FullAccounts 2021-10-01 2022-09-30 12189862 c:PrivateLimitedCompanyLtd 2021-10-01 2022-09-30 12189862 c:Micro-entities 2021-10-01 2022-09-30 iso4217:GBP xbrli:pure

Registered number: 12189862









MOLECULES TO MEDICINES LTD







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 30 SEPTEMBER 2022

 
MOLECULES TO MEDICINES LTD
REGISTERED NUMBER: 12189862

STATEMENT OF FINANCIAL POSITION
AS AT 30 SEPTEMBER 2022

2022
2021
£
£


Fixed assets
2,114
3,159

Current assets
106,593
91,929

Creditors: amounts falling due within one year
(12,777)
(16,340)

Net current assets
 
 
93,816
 
 
75,589

Total assets less current liabilities
95,930
78,748


Net assets
95,930
78,748



Capital and reserves
95,930
78,748


Notes


General information

The principal activity of Molecules to Medicines Limited is biotechnology research.
The company is a private company limited by shares and is incorporated in England and Wales.
The registered office address is 33 St. Georges Road, London, England, N13 4AT.


Average number of employees

The average monthly number of employees, including directors, during the year was 1 (2021 - 1).

The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to entities subject to the micro-entities' regime.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.





 
Page 1

 
MOLECULES TO MEDICINES LTD
REGISTERED NUMBER: 12189862
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 30 SEPTEMBER 2022


The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




................................................
N Miller
Director
Date: 17 May 2023

 
Page 2